CRBU Share Price Performance
US$0
-0.82 (-100.00%)
Price US$0
Share Pricen/a
Analysis Article • May 13
Caribou Biosciences, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 33 Fair Values set on narratives written by author
CRBU Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Caribou Biosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -1.36
- -859.77%
- -1,189.14%
- 0%
About CRBU
- Founded
- 2011
- Employees
- 97
- CEO
- WebsiteView website
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
